The EPS whiff matters because it punctures the easiest version of the TMDX story: rapid growth, expanding logistics, and operating leverage arriving on schedule. In the first quarter of 2026, TransMedics posted revenue of $173.9 million, up 21% year over year, which is the sort of top-line number growth investors usually applaud. Instead, the applause got replaced by a trap door. GAAP diluted EPS fell to $0.20 from $0.70 a year earlier, while adjusted diluted EPS fell to $0.30 from $0.74. The stock responded the way expensive growth stocks respond when profit quality suddenly looks less magical: badly.
That reaction was not irrational. It was delayed.
The core problem is not that the business stopped growing. It didn’t. The problem is that growth is getting more expensive at the exact moment the market is less willing to pay venture-style multiples for “platform” stories with airline fuel attached. TransMedics’ gross margin slipped to 58.2% from 61.5%, and operating margin collapsed to 7.6% from 19.1%. Adjusted operating margin was 10.4%, down from 20.7%. That is not a rounding error. That is a business choosing to spend hard while investors were still underwriting a smoother glide path.
Management did not hide the spending. In fact, the company basically told you where the pressure came from. The first-quarter release said gross margin was hit by investments to support growth and scale plus higher supply-chain and operating costs. The 10-Q fills in the less glamorous details: product gross margin fell to 77% from 82% because of product mix and higher freight costs, while service gross margin fell to 27% from 29% because of increased labor expense. Translation: this is a very good business that is becoming a more operationally messy one as it builds the network around the device.
And that network is the whole debate. TMDX is no longer just selling organ-preservation hardware and disposables. It is building a logistics system around organ procurement, perfusion management, and aviation. In Q1, service revenue rose 19.3% to $66.0 million, and the company said it owned 22 aircraft as of March 31, 2026, covering 82% of NOP flight missions with owned aircraft. That may strengthen control over the transplant workflow over time. It also means investors now own a med-tech company with a meaningful aviation and logistics cost structure. Wonderful if it scales. Unforgiving if it doesn’t.
There is a bull case here, and it is not stupid. Revenue is still compounding fast, and management reiterated full-year 2026 revenue guidance of $727 million to $757 million, implying roughly 20% to 25% growth. Liver remained strong, with Q1 liver revenue up 27.7% year over year to $139.0 million. Service revenue is growing, international ambitions are expanding, and the company recently announced an intended strategic investment in Germany-based PAD Aviation to build a European transplant logistics network. If this becomes the dominant end-to-end transplant infrastructure asset, today’s margin compression may eventually look like a tolerable toll.
But bulls should stop pretending every dollar of revenue deserves the same multiple. Device revenue and logistics revenue are not twins. One is typically cleaner, more scalable, and structurally higher margin. The other can be strategically valuable while still being operationally hungry. Q1 made that distinction impossible to ignore. When operating expenses jump to $87.9 million from $60.8 million, you don’t get to wave it away with “investment phase” forever. At some point, investment phase needs to grow up and become earnings phase.
The balance sheet is not the immediate problem. TransMedics ended the quarter with cash of $461.7 million, and the 10-Q shows operating cash flow of $24.5 million in Q1, versus negative $2.9 million in the prior-year quarter. That helps. But it is also true that the same 10-Q shows free cash flow turning negative in the quarter as investing cash outflows reached $36.7 million. Again: not fatal, just not the profile investors were paying peak multiples for.
There is also an governance-quality wrinkle worth respecting. In its 2025 annual report, TransMedics disclosed that its auditor issued an adverse opinion on internal control over financial reporting because of a material weakness tied to inventory movement within its manufacturing network. That does not automatically mean the numbers are wrong. It does mean this is not the moment to grant management a premium for flawless execution while the company is adding complexity across manufacturing, logistics, and international expansion.
So, should you buy the stock?
My answer is not yet for most investors, but it is getting interesting.
At roughly the low-$70s on May 6, 2026 after a one-day drop of about 24%, the easy air has come out of the name. Good. It needed to. But a stock falling from silly to less silly is not automatically a bargain. The right question is whether this quarter was a temporary digestion period inside a still-exceptional model, or evidence that TMDX is becoming a lower-margin logistics-heavy operator than the market once imagined.
If you already own it, I would lean hold, not sell in a panic. The business still has real growth, real cash, and real strategic assets. If you do not own it, I would resist the hero trade and wait for evidence that margin damage is stabilizing, not merely explained. Cheap stories rarely need a conference-call adjective to work.
What to watch: over the next two quarters, does TMDX prove that logistics scale lifts utilization without permanently capping gross and operating margins, or has the company quietly traded a premium med-tech model for a more complicated, lower-multiple transportation-enabled one?